anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Duloxetine hydrochloride, USP is available as delayed-release capsules in the following strengths:

20 mg – Each capsule with blue opaque cap and body, printed with  and 2890 on both cap and body in black ink contains 22.4 mg of duloxetine hydrochloride, USP equivalent to 20 mg of duloxetine. Capsules are supplied in bottles of 60 (NDC 0228-2890-06).

30 mg – Each capsule with gray opaque body and blue opaque cap, printed with  and 2891 on both cap and body in black ink contains 33.7 mg of duloxetine hydrochloride, USP equivalent to 30 mg of duloxetine. Capsules are supplied in bottles of 30 (NDC 0228-2891-03) and bottles of 500 (0228-2891-50).

60 mg – Each capsule with gray opaque body and white opaque cap, printed with  and 2892 on both cap and body in black ink contains 67.3 mg of duloxetine hydrochloride, USP equivalent to 60 mg of duloxetine. Capsules are supplied in bottles of 30 (NDC 0228-2892-03) and bottles of 1,000 (0228-2892-96).
If using VIGADRONE powder for oral solution, physicians should review and discuss the Medication Guide and instructions for mixing and giving VIGADRONE with the patient or caregiver(s). Physicians should confirm that patients or caregiver(s) understand how to mix VIGADRONE powder with water and administer the correct daily dose.

Empty the entire contents of each 500 mg packet into a clean cup, and dissolve in 10 mL of cold or room temperature water per packet. Administer the resulting solution using the 3 mL or 10 mL oral syringe provided by the pharmacy [see How Supplied/Storage and Handling (16.1)]. The concentration of the final solution is 50 mg/mL. 

Table 3 below describes how many packets and how many milliliters (mL) of water will be needed to prepare each individual dose. The concentration after reconstitution is 50 mg/mL.

Discard the resulting solution if it is not clear (or free of particles) and colorless. Each individual dose should be prepared and used immediately. Discard any unused portion of the solution after administering the correct dose.
Methods of synthesizing  100 Mo 2 C and  99m TcO 4   −  are disclosed. Methods of  100 Mo 2 C generation involve thermally carburizing  100 MoO 3 . Methods of  99m TcO 4  generation involve proton bombardment of  100 Mo 2 C in a cyclotron. Yields of  99m TcO 4  can be increased by sintering  100 Mo 2 C prior to bombardment. The methods also include recycling of  100 Mo 2 C to form  100 MoO 3 . SPECT images obtained using  99m TcO 4  generated by the disclosed methods are also presented.
Artificial mineral waters are prepared by dissolving in water a solid composition comprising at least one enzyme which ameliorates food metabolism and substances causing effervescence when dissolved in water.  The enzyme may be a protease, an amylase, a cellulase, or a lipase. The substances causing effervescence may comprise KHCO3 or K2CO3 and a compound giving an acid reaction in aqueous solution e.g. citric acid. The solid composition may be in tablet form, and a typical formulation comprises pancreatic protease, amylase, cellulase and lipase, glucuronamide, Vitamin C, sodium monofumarate, and polyethylene glycol 6000.  The tablet may have an inner core comprising lipase coated with a protective coating e.g. cellulose and an outer core comprising other enzymes and effervescent agents.ALSO:Enzyme compositions, which on dissolution in water produce effervescent compositions capable of facilitating digestion comprise at least one enzyme which ameliorates food metabolism and substances which cause effervescence when dissolved in water. The enzyme may be a protease, an amylase, a cellulase, or a lipase.  The substances causing effervescence may comprise K2CO3 or KHCO3 and a compound giving an acid reaction in aqueous solution, e.g. citric acid.  The compositions may be in tablet form, the tablet having an inner core comprising lipase coated with a protective coating, e.g. cellulose, and an outer core comprising other enzymes and the effervescent agents. A typical example comprises a tablet consisting of pancreatic protease, amylase, cellulase, and lipase, glucuronamide, vitamin C, sodium monofumarate, and polyethylene glycol 6000 as excipient.
The invention discloses a bone setting prescription capable of promoting callus to grow quickly, and a preparation method thereof. According to the formula, the bone setting prescription comprises the following components in percentage by weight: 50% of radix isatidis, 30% of Hibiscus syriacus L, 10% of wide tinospora sinensis, and 10% of curcuma zedoaria. Rosc. The preparation method of the bone setting prescription comprises the following steps: weighing fresh herbs of all components according to the formula, mixing fresh herbs to be smashed into the mud, and spreading the prescription at an affected area. According to 3005 clinical application cases, by the adoption of the prescription, the shortest healing time of the bone fracture is 15 days, and the longest healing time of the bone fracture is 30 days based on age difference of patients; the total effective rate is 99%. A medicine adopting the prescription to treat the bone fracture has the characteristics of reducing swelling and relieving pain, promoting rapid growth of callus, and realizing a remarkable curative effect; the prescription is suitable for clinical medicine for treating bone fracture, and is also suitable for the development of herbal medicine planting and production of a pharmaceutical factory.
Patients from this group will receive the kinesio Taping® Tex Gold tape according to the manufacturer's instructions. Kinesio Taping will be applied for the purpose of inhibiting the erector spinal muscle from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae with 10 to 15% tension (paper-OFF) in a "I" position bilaterally.
Immunogenic Escherichia coli O157:H7 (0157) proteins expressed during infection of a mammal, are described. In particular, 0157 proteins expressed specifically in vivo during human and cattle infection were identified. These proteins, mapped to the backbone, O-islands (OIs) and pO157. Because these-proteins are expressed during infection, and might help pathogens adapt to and counter hostile in vivo environments, those proteins identified in this study are useful as targets for drug and vaccine development. Also, such proteins are useful as markers of 0157 infection in stool specimens. Also described are methods of identifying immunogenic proteins.
According to the invention, a concrete dosage formula is implemented and developed in clinical researches. The dosage formula employs perfluorocarbon gas which can provide a substantially enhanced image and a long duration, and combines the gas into polymer particles, such that an ultrasonic contrast medium is prepared. The dosage formula comprises particles formed by biocompatible polymers and perfluorocarbon. Preferably, lipid is mixed in the polymer, and perfluorocarbon is in a form of gas under a body temperature. A patient is administrated with the particles with a dosage effective to enhanced ultrasonography. The duration in the ventricle is longer than 5min and/or the duration in the cardiac muscle is longer than 1min, and the dosage range is 0.025-8.0mg/kg (particles/body weight), and preferably 0.05-4.0mg/kg (particles/body weight). The dosage formula is generally provided in small bottles. In a typical formula, a dosage formula is formed by dry powder which needs to be re-prepared by using sterile water before use. Specifically, water is added to a small bottle or a syringe; the bottle or the syringe is shaken, such that isotonic or isoosmotic particle suspension fluid is formed.
Branched polyanhydrides that have superior properties for use in the controlled delivery of substances, prepared by the polymerization of a dicarboxylic acid monomer and a branching agent. The branching agent is a polycarboxylic acid monomer such as 1,3,5-benzenetricarboxylic acid ("BTC"), or an oligomerized fatty acid trimer. Alternatively, the branching agent is a polycarboxylic acid polymer such as poly(acrylic acid) ("PAA"). These branched polymers have significantly higher molecular weights and lower specific viscosity than linear polymers prepared under similar conditions. A major advantage of branched polyanhydrides is that the degradation and release kinetics can be substantially altered without significantly changing the physical properties of the polymer relative to the corresponding linear polymer. By manipulating both the diacid and the branching agent, a wide variety of biodegradable controlled delivery devices for diverse applications can be prepared.
The utility model relates to a traditional Chinese medicine pillow with functions of building brain and sleeping peacefully, belonging to the field of medical supplies. The pillow comprises a pillow sleeve 1, a traditional Chinese medicine pillow core 2 and big pearl cotton 3. The traditional Chinese medicine pillow is characterized in that the pillow sleeve 1 is made of non-woven cloth with good air permeability; the traditional Chinese medicine pillow core has the following eighteen traditional Chinese medicines: poria with hostwood, radix polygalae, spina date seeds, tuber fleeceflower stem, feculae bombycis, fructus schisandrae chinensis, alpinia oxyphylla, chrysanthemum, folium mori, herba lophatheri, calamus, herba asari, albizzia julibrissin durazz, eriobotrya japonica, rhizoma et radix notopterygii, radix saposhnikoviae, magnolia flower and benzoinum. The pillow has the effects of tonifying noema, building brain, sleeping peacefully, inducing resuscitation and dredging collaterals. The flexible filler big pearl cotton 3 is filled between the pillow sleeve 1 and the traditional Chinese medicine pillow core 2, so that the heat preservation effect is realized, and the patient can feel soft and comfortable. The traditional Chinese medicine pillow is simple in structure, is convenient in use, and is suitable for overworking brain patients, insomnia patients or neurasthenia patients.
Leukopenia and/or agranulocytosis and convulsive seizures have been reported but are infrequent. In schizophrenic patients with epilepsy, anticonvulsant medication should be maintained during treatment with thioridazine. Pigmentary retinopathy, which has been observed primarily in patients taking larger than recommended doses, is characterized by diminution of visual acuity, brownish coloring of vision, and impairment of night vision; examination of the fundus discloses deposits of pigment. The possibility of this complication may be reduced by remaining within the recommended limits of dosage.

Where patients are participating in activities requiring complete mental alertness (e.g., driving) it is advisable to administer the phenothiazines cautiously and to increase the dosage gradually. Female patients appear to have a greater tendency to orthostatic hypotension than male patients. The administration of epinephrine should be avoided in the treatment of drug-induced hypotension in view of the fact that phenothiazines may induce a reversed epinephrine effect on occasion. Should a vasoconstrictor be required, the most suitable are levarterenol and phenylephrine.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of neuroleptic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.
Rivaroxaban monotherapy 20 mg/day for 5 days followed by Rivaroxaban 20 mg/day + Warfarin. 10 mg/day for \>= 2 to \<= 4 days concomitant therapy, then Warfarin monotherapy 0-15 mg/day for 4 days (Treatment Period 1). A 14-day washout period will separate Treatment Periods 1 and 2.
Gastric cancer is one of the main cancer-related causes of death in the world. There is more than one standard treatment for non-metastatic advanced disease. Among the therapeutic alternatives there is high level of evidence to recommend surgery followed by chemoradiotherapy or chemotherapy and for perioperative chemotherapy. These strategies have not been compared in adequate powered trials, so there are important regional differences in their use. Postoperative chemotherapy with oxaliplatin based chemotherapy may offer some advantages in limited resource settings, because of its lower logistic requirements and it could be specially useful in centers with high quality surgery. On the other hand one of its most important downsides could be a higher impact on quality of life particularly related to oxaliplatin induced neuropathy which can last long after the end of treatment. This is a prospective observational trial in which after consent subjects are going to be evaluated with the EORTC (European Organization for Research and Treatment of Cancer) questionnaires C30 and CIPN20 during FOLFOX (5-fluorouracil/leucovorin with oxaliplatin) adjuvant treatment.
Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria have been reported with cyclophosphamide. Medical and/or surgical supportive treatment may be required to treat protracted cases of severe hemorrhagic cystitis. Discontinue cyclophosphamide therapy in case of severe hemorrhagic cystitis. Urotoxicity (bladder ulceration, necrosis, fibrosis, contracture and secondary cancer) may require interruption of cyclophosphamide treatment or cystectomy. Urotoxicity can be fatal. Urotoxicity can occur with short-term or long-term use of cyclophosphamide.  
Before starting treatment, exclude or correct any urinary tract obstructions [see Contraindications (4)]. Urinary sediment should be checked regularly for the presence of erythrocytes and other signs of urotoxicity and/or nephrotoxicity. Cyclophosphamide Injection should be used with caution, if at all, in patients with active urinary tract infections. Aggressive hydration with forced diuresis and frequent bladder emptying can reduce the frequency and severity of bladder toxicity. Mesna has been used to prevent severe bladder toxicity.
A pilot and feasibility randomized trial of two medication reminder systems for patients with heart failure (HF). The investigators believe that medication reminder systems will improve adherence and will reduce the effects of cognitive impairment on medication adherence. The investigators believe that patients will accept and use a medication reminder system, but the investigators cannot specify which system will be preferred. Each has different features which may be perceived as more or less desirable.

The investigators will enroll 60 patients with HF and randomize them to four conditions in a 2 (device 1 versus device 2) by 2 (Active versus Passive) design. After enrollment in the trial, patients will be consented and will complete pretesting at Summa Health System in the Center for Clinical Trials. They will primarily undergo brief computerized cognitive testing, complete self-report measures (e.g., quality of life, depression, self-management related social support), and will give consent for medical information to be collected from their electronic medical record. They will then be randomized to condition. In-home training will be provided regarding how to use the equipment. Medication adherence will be monitored for 28 days, followed by an in-home post-test (all pre-test measures) during which the equipment is returned.
PCT No. PCT/GB89/01545 Sec. 371 Date Aug. 28, 1991 Sec. 102(e) Date Aug. 28, 1991 PCT Filed Dec. 29, 1989 PCT Pub. No. WO90/07324 PCT Pub. Date Jul. 12, 1990.The invention provides a multiphase pharmaceutical composition for combatting an anorectal disease comprising at least one phase containing one or more medicaments for combatting said disease and at least one phase adapted for delayed release of a silicone oil whereby application of said composition at a region affected by said disease deposits said medicament or medicaments thereon and a layer of silicone oil is formed thereover, so protecting the medicaments from erosion by aqueous media.
In addition to the home exercise program, Myofascial Induction Techniques (MIT) group patients will have MIT applied to the cervical and upper thoracic regions by a physiotherapist trained and experienced in myofascial treatments. The application will be once a week for 8 weeks, with an average duration of 35-45 minutes.
This invention provides a novel agent for preventing and ameliorating constipation. It very effectively ameliorates constipation symptoms without any side effects. Namely, an agent for preventing and ameliorating constipation contains a water-containing gel of a polyvalent metal alginate. It is in the form of spherical or cocoon-shaped particles with a minor diameter of from 1 to 10 mm and an aspect ratio (major diameter/minor diameter) of from 1 to 2.5. This water-containing gel of a polyvalent metal alginate is obtained by dropping an aqueous solution of sodium alginate into an aqueous solution of a polyvalent metal salt. If needed, it is preserved in water and/or a hydrogel compound of a natural compound with a free acid group. Consequently, it can be captured after reacting with a basic compound.
Macro or High Dosing Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study. (These participants can still be in the study and will only have to re-do a baseline COW's on the day they come back to the clinic, which will then be considered their day 1).
Asthma is a chronic inflammatory disorder of the airways characterized by reversible airflow obstruction. Fourteen million persons (6.4%) in the United States report having asthma, and from 1980 to 1994 the prevalence of self-reported asthma in the United States increased by 75%. A major factor in the pathogenesis of asthma is the development of an allergic inflammatory response to inhaled antigens. Interleukin-4 (IL-4) plays a key role in this response by promoting IgE production, upregulating IgE receptors, upregulating adhesion receptors such as VCAM-1, promoting Th2 cell development and increasing mucus secretion. Soluble recombinantly produced IL-4R (sIL-4R) has been shown to bind and inactivate IL-4, both in vitro and in animal models. As part of a multicenter trial, 20 subjects at the NIH site will receive 0.9 mg., 1.8 mg. sIL-4R or placebo once weekly for 12 weeks in a double blind placebo controlled study. Study drug will be delivered via the AERx aerosol drug delivery device. The primary objective of the study will be to evaluate efficacy as measured by FEV1. Secondary objectives will include changes in FVC, FEF 27-75, peak flow, bronchodilator usage, asthma symptoms, quality of life scores, immunologic and inflammatory markers, pharmacokinetics, safety and immunogenicity. The study population will consist of moderate to severe asthmatics on (Beta)-agonist monotherapy with an FEV1 of 50-80% of predicted. After 12 weeks of study drug, subjects will be followed for an additional 8 weeks.
The invention discloses a traditional Chinese medicine composition used for treating aplastic anemia. The composition is composed of the raw materials of, by weight: 10-12 parts of pilose asiabell root, 4-6 parts of common jujube, 2-4 parts of Mongolian milkvetch root, 5-7 parts of ligusticum, 2-4 parts of prepared rehmannia root, 7-9 parts of Szechwan lovage rhizome, 10-12 parts of medlar, 3-5 parts of largehead atractylodes rhizome, 2-4 parts of tuber fleeceflower root, 5-7 parts of turtle shell, 3-5 parts of epimedium, 2-4 parts of ass-hide gelatin, 5-7 parts of dried human placenta, 1-3 parts of suberect spatholobus stem, 3-5 parts of kadsura root-bark, 5-7 parts of snakegourd root, 2-4 parts of cuttlebone, 6-8 parts of kalimeris indica, 3-5 parts of fragrant plantain lily, 1-3 parts of Japanese raspberry root, 1-3 parts of jatamana valeriana rhizome, and 8-10 parts of lotus seedpod. The traditional Chinese medicine composition is provided with a traditional Chinese medical science theory. The medicine materials are formulated such that qi-benefiting, yin-nourishing, heat-clearing, blood-cooling, stasis-removing, bleeding-stopping, spleen-invigorating, and stomach-nourishing functions are provided. With the medicine composition, bone marrow hematopoietic function can be effectively stimulated, and immunity can be regulated. The medicine composition has good clinical treatment effect in treating aplastic anemia, and has the advantages of low cost, good treatment effect, and reoccurrence prevention.
If they are randomized into the treatment arm, they will be prescribed with a 2-week VLCD that will begin 2 weeks prior to the scheduled elective surgery. Patients will be required to pay for the meal replacements.
PURPOSE: Spasticity is common in multiple sclerosis (MS), often leading to functional limitations and disability. We developed a conceptual model of spasticity in MS integrating expert opinion, recent literature, and experiences of clinicians and people with MS spasticity.
METHODS: A conceptual model was developed based on a targeted literature review of articles published between 2014 and 2019, followed by input from clinicians, then input from participants with MS spasticity. Multidisciplinary experts on spasticity provided guidance at each step.
RESULTS: Key concepts of the integrated spasticity conceptual model included: moderators; triggers; modifiers; treatment; objective manifestations; subjective experience; physical, functional, social, and emotional/psychological impacts; and long-term consequences. Participants with MS spasticity most frequently endorsed spasms, tightness, and pain as descriptors of spasticity. Some participants with MS spasticity had difficulty distinguishing spasticity from other MS symptoms (e.g. muscle weakness). Some triggers, emotional/psychological impacts, and long-term consequences of spasticity reported by participants with MS spasticity were not previously identified in the published literature.
CONCLUSIONS: This conceptual model of spasticity, integrating published literature with the experience of clinicians, people with MS spasticity, and experts, demonstrates the complex, multidimensional nature of MS spasticity. This model may be used to improve clinician-patient dialogue, research, and patient care.